Trial Profile
A clinical study of recurrent ovarian ovarian cancer in the treatment of platinum resistance in apatinib tablet
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 15 Jun 2017 New trial record